Pyrazinamide inhibits the eukaryotic-like fatty acid synthetase I (FASI) of Mycobacterium tuberculosis

Nature Medicine

Volumn 6, Issue 9, 2000, Pages 1043-1047

  Zimhony, Oren ^a   Cox, Jeffery S ^a   Welch, John T ^b   Vilchèze, Catherine ^a   Jacobs Jr , William R ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b STATE UNIVERSITY OF NEW YORK   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYL COENZYME A; FATTY ACID SYNTHASE; ISONIAZID; MYCOLIC ACID; PYRAZINAMIDE; PYRAZINOIC ACID; RIFAMPICIN;

ANTIBIOTIC RESISTANCE; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL GENE; BACTERIAL INFECTION; CONTROLLED STUDY; DRUG TARGETING; ENZYME INHIBITION; FATTY ACID SYNTHESIS; MYCOBACTERIUM; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; TUBERCULOSIS;

ANIMAL; ANTITUBERCULAR AGENTS; BACTERIAL PROTEINS; ENZYME INHIBITORS; FATTY ACID SYNTHETASE COMPLEX; HUMAN; MYCOBACTERIUM TUBERCULOSIS; PRODRUGS; PYRAZINAMIDE; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.; TUBERCULOSIS, PULMONARY;

EID: 0033834868     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/79558     Document Type: Article

References (32)

1. Bass Jr, J.B. et al. Treatment of tuberculosis infection in adults and children. Am. J. Respir. Crit. Care. Med. 149, 1359-1374 (1994).
2. Steele, M.A. & Des Prez, R.M. The role of pyrazinamide in tuberculosis chemotherapy. Chest. 94, 845-850 (1988).
3. Konno K., Feldmann, F.M. & McDermott, W. Pyrazinamide susceptibility and amidase activity of tubercle bacilli. Am. Rev. Respir. Dis. 95, 461-469 (1967).
4. Cynamon, M.H., Speirs, R.J. & Welch, J.T. In vitro antimycobacterial activity of 5-chloropyrazinamide. Antimicrob. Agents Chemother. 42, 462-463 (1998).
5. Fernandes, N.D. & Kolattukudy, P.E. Cloning, sequencing and characterization of a fatty acid synthase -encoding gene from Mycobacterium tuberculosis variant BCG. Gene. 170, 95-99 (1996).
6. Brindley, D.N., Matsumura, S & Bloch, K. Mycobacterium phlei fatty acid synthetase a bacterial multienzyme complex. Nature 224, 666-669 (1969).
7. Kushner, S. et al. Experimental chemotherapy of tuberculosis. The synthesis of pyrazinamide and related compounds. J. Am. Chem. Soc. 74, 3617-3621 (1952).
8. Scorpio, A & Zhang, Y. Mutations in pncA a gene encoding pyrazinamidase/nicotinamidase cause resistance to the antituberculosis drug pyrazinamide in M. tuberculosis. Nature Med. 2, 662-667 (1996).
9. Scorpio, A. et al. Characterization of the pncA mutations in pyrazinamide-resistant Mycobacterium tuberculosis. Antimirob. Agents. Chemother. 41, 540-543 (1997).
10. Good, R.C., Silcox, V.A., Kilborn, J.O & Plikaytis, B.D. Identification and drug susceptibility test results for Mycobacteria species. Clin. Microbiol., Newslett. 7, 133-136 (1985).
11. McDermott W. & Tompsett R. Activation of pyrazinamide and nicotinamide in acidic environments in vitro. Am Rev. Tuber. 70, 748-754 (1954).
12. Zhang, Y., Scorpio, A., Nikaido, H & Sun, Z. Role of Acid pH and deficient efflux of pyrazinoic acid in unique susceptibility of Mycobacterium tuberculosis to pyrazinamide. J. Bacteriol. 181, 2044-2049 (1999).
13. Cynamon, M.H. et al. Pyrazinoic acid esters with broad spectrum in vitro antimycobacterial activity. J. Med. Chem. 38, 3902-3907 (1995).
14. Banerjee., A. et al. inhA, a gene encoding a target for isoniazid and ethionamide in Mycobacterium tuberculosis. Science 263, 227-230 (1994).
15. Telenti, A. et al. The emb operon, a gene cluster of Mycobacterium tuberculosis involved in resistance to ethambutol. Nature Med. 3, 567-570 (1997).
16. Kolattukudy, P.E., Fernandes, N.D., Azad., A.K., Fitzmaurice, A.M & Sirakova, AT. Biochemistry and molecular genetics of cell-wall lipid biosynthesis in mycobacteria. Mol. Microbiol. 24, 263-270 (1997).
17. Cole, S.T. et al. Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature 393, 537-544 (1998).
18. Kikuchi, S., Rainwater, D.L & Kolattukudy, P.E. Purification and characterization of an usually large fatty acid synthase, from Mycobacterium tuberculosis vor. bovis BCG. Arch. Biochem. Biophys. 295, 318-326 (1992).
19. Anderson, R.J. The chemistry of the lipoids of tubercle bacilli. J. Biol. Chem. 135, 327-337 (1929).
20. Folch, J., Lees, M. & Sloane-Stanley, G.H.S. A simple method for the isolation and purification of total lipids from animal tissues. J. Biol. Chem. 226, 497-509 (1957).
21. Slayden, R. A. et al. Antimycobacterial action of thiolactomycin: an inhibitor of fatty acid and mycolic acid synthesis. Antimicrob. Agents. Chemother. 40, 2813-2819 (1996).
22. Omura, S. Cerulenin. Methods. Enzymol. 72, 520-532 (1981).
23. Mdluli, K. et al. Inhibition of a Mycobacteria tuberculosis ∃-Ketoacyl ACP synthase by isoniazid. Science 280, 1607-1610 (1998).
24. Takayama, K., Schonoes, H.K., Armstrong, E.L & Boyle, R.D. Site of inhibitory action of isoniazid in the synthesis of mycolic acids in Mycobacterium Tuberculosis. J. Lipid Res. 16, 308-317 (1975).
25. Mehta, A., Oeser, A.M., Carlson, M.G. Rapid quantitation of free fatty acids in human plasma by high-performance liquid chromatography. J. Chromatog. B. 719, 9-23 (1998).
26. Hagen, S.R, Thompson J.D. Analysis of mycolic acids by high-performance liquid chromatography and fluorimetric detection. Implication for the identification of mycobacteria in clinical samples. J. Chromatog. A. 692, 167-172 (1995).
27. Bloch, K. Fatty acid synthases from Mycobacterium phlei. Methods Enzymol. 35, 84-90 (1975).
28. Centers for Disease Control and Prevention. Prevention and treatment of tuberculosis among patients infected with Human Immunodeficiency Virus: Principles of therapy and revised recommendations. MMWR. Morb. Mortal. Wkly. Rep. 47 (RR20) 1-51 (1998).
29. Mitchison, D.A. The action of antituberculosis drugs in short-course chemotherapy of M. tuberculosis. Tubercle 66, 219 (1985).
30. Grosset, J. The sterilizing value of rifampin and pyrazinamide in experimental short course chemotherapy. Tubercle 59, 287-297 (1978).
31. McCune, R.M., Jr., Tompsett, R., Mcdermott, W.J. The fate of Mycobacterium tuberculosis in mouse as determined by the microbial enumeration technique. J. Exp. Med. 104, 763-803 (1956).
32. Salfinger, M., Crowle, A.J. & Reller, L.B. Pyrazinamide and pyrazinoic acid activity against tubercle bacilli in cultured human macrophages and in the BACTEC system. J. Infect, Dis. 162, 201-207. (1990).